Skip to main content

Postherpetic Neuralgia News

Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from t...

FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions

October 12, 2017 - Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily...

GSK and XenoPort Receive FDA Approval for Horizant for Postherpetic Neuralgia

LONDON & RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun 7, 2012 - GlaxoSmithKline plc and XenoPort, Inc. announced today that the United States (US) Food and Drug...

NeurogesX Receives FDA Approval of Qutenza (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)

SAN MATEO, Calif., Nov. 16 /PRNewswire-FirstCall/ – NeurogesX, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza (capsaicin) 8% patch, the first and only...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Neuralgia

Related drug support groups

gabapentin, Lyrica, pregabalin, Neurontin, clonidine, nortriptyline, Lidoderm